<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Therapies with <z:chebi fb="0" ids="6801">metformin</z:chebi>, <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi>, or insulin improve glycemic control in the short term but do not prevent progressive islet beta-cell failure or long-term deterioration in glycemia </plain></SENT>
<SENT sid="1" pm="."><plain>Our goal was to evaluate, in patients recently diagnosed with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (&lt;3 years), the long-term efficacy of monotherapy with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> on glycemic control and on the progression of pathophysiological abnormalities associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> as compared with <z:chebi fb="0" ids="6801">metformin</z:chebi> or <z:chebi fb="0" ids="5441">glyburide</z:chebi> monotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A <z:mp ids='MP_0002055'>Diabetes</z:mp> Outcome Progression Trial (ADOPT) is a randomized, double-blind, parallel-group study consisting of a screening visit, a 4-week placebo run-in, a 4-year treatment period, and an observational follow-up of approximately 3,600 drug-na√Øve patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> diagnosed within the previous 3 years </plain></SENT>
<SENT sid="3" pm="."><plain>After run-in, patients will be randomized to <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, <z:chebi fb="0" ids="5441">glyburide</z:chebi>, or <z:chebi fb="0" ids="6801">metformin</z:chebi> titrated to the maximum effective daily doses (8 mg <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, 15 mg <z:chebi fb="0" ids="5441">glyburide</z:chebi>, or 2 g <z:chebi fb="0" ids="6801">metformin</z:chebi>) </plain></SENT>
<SENT sid="4" pm="."><plain>The primary outcome is time to monotherapy failure, defined as the time following titration to the maximal effective or tolerated dose when fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> exceeds 180 mg/dl (10 mmol/l) </plain></SENT>
<SENT sid="5" pm="."><plain>Secondary outcomes include measures of islet beta-cell function, insulin sensitivity, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, changes in urinary albumin excretion, plasminogen activator inhibitor-1 antigen, fibrinogen, and C-reactive protein </plain></SENT>
<SENT sid="6" pm="."><plain>Safety and tolerability will also be evaluated </plain></SENT>
<SENT sid="7" pm="."><plain>Patient-reported outcomes and resource utilization data will be collected and analyzed </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: ADOPT will provide data on the effect of mechanistically differing treatment options on metabolic control, beta-cell function, and markers of macrovascular disease risk in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>